M701 Bispecific Antibody Shows Promise for Malignant Ascites Treatment in Phase II Trial

What Promising Advances Does M701 Offer in Malignant Ascites?

A Phase II Trial Shows Promising Results for M701 in Malignant Ascites Treatment

Intraperitoneal administration of M701, a novel bispecific antibody targeting EpCAM and CD3, has demonstrated significant improvement in puncture-free survival for patients with malignant ascites in a recent Phase II clinical trial. This treatment approach represents a potential breakthrough for patients with advanced epithelial cancers who currently face limited therapeutic options for managing this challenging condition.

Malignant ascites, characterized by the accumulation of fluid in the peritoneal cavity due to cancer, significantly impairs quality of life for patients with advanced gastrointestinal and gynecological malignancies. The condition causes abdominal pain, breathing difficulties, and other complications that worsen as the disease progresses. Currently, the standard approach involves repeated paracentesis or drainage procedures, which provide only temporary relief and carry risks of infection and fluid imbalance. Despite advances in cancer treatments, few options specifically target the management of malignant ascites, with catumaxomab being the only previously approved therapy before its market withdrawal in 2017 (though it was reapproved in 2025).

How Was the Phase II Trial Structured?

The multicenter randomized controlled trial conducted across 34 hospitals in China enrolled 84 patients with malignant ascites from gastrointestinal or ovarian cancers who had either failed at least two lines of systemic treatment or were platinum-resistant in the case of ovarian cancer. Patients were randomized in a 1:1 ratio to receive either intraperitoneal M701 following paracentesis (starting with 50 μg on day 1, followed by 400 μg on days 4, 11, and 18) or paracentesis alone. Both groups continued to receive appropriate systemic anticancer therapies according to Chinese clinical practice guidelines.

M701 represents a significant advancement in bispecific antibody design. It features a Fab-scFv-Fc structure with the Fab moiety targeting EpCAM and the scFv moiety targeting CD3. The antibody was engineered with moderate affinity for CD3 to balance T-cell activation with reduced cytokine release, potentially improving its safety profile compared to earlier bispecific antibodies. Preclinical studies demonstrated that M701 effectively bridges T cells to EpCAM-expressing tumor cells, inducing potent and specific cytotoxicity against cancer cell lines with high EpCAM expression while sparing those with low or no EpCAM expression.

What Efficacy Endpoints Illustrate M701's Benefit?

The trial's primary endpoint was puncture-free survival (PuFS), defined as the time to first re-puncture or drainage due to intolerance of malignant ascites, or death after the last drainage from days 1-18. Results showed that patients in the M701 group achieved a median PuFS of 75 days compared to just 25 days in the control group (HR 0.43, 95% CI: 0.22-0.81, p=0.0065). The one-month and two-month PuFS rates were significantly higher in the M701 group (65.2% vs. 40.6% at one month; 50.3% vs. 22.1% at two months), indicating substantial clinical benefit in delaying the need for repeated procedures.

Notably, the benefit was even more pronounced in patients with higher baseline relative lymphocyte counts (RLC ≥13%), with median PuFS extending to 125 days in the M701 group versus 22 days in the control group (HR 0.23, 95% CI: 0.10-0.55, p=0.0003). This subgroup also demonstrated significant overall survival benefit (median OS 152 days vs. 76 days, HR 0.46, p=0.0155), suggesting that baseline lymphocyte status may serve as a potential biomarker for treatment response.

Is the Safety and Tolerability Profile of M701 Favorable?

The safety profile of M701 was manageable, with comparable rates of treatment-emergent adverse events between groups (94.0% in M701 vs. 92.5% in control). The most common serious adverse events in the M701 group included gastrointestinal disorders (16.0%), laboratory abnormalities (14.0%), and blood/lymphatic system disorders (12.0%). While M701 was associated with higher rates of hematologic abnormalities, these were generally transient and reversible. Cytokine release syndrome, a concern with T-cell engaging therapies, occurred in only 4% of M701-treated patients and was limited to grades 1-2.

Pharmacokinetic analyses revealed minimal systemic exposure, with peak serum concentrations averaging just 6.53 ng/mL on day 18, while ascites concentrations reached 26.5 ng/mL. This localized activity likely contributes to the favorable safety profile observed. Anti-drug antibody development was noted in 64.3% of patients' serum samples, though titers in ascites were considerably lower, with the ratio between ascites and serum being approximately 0.1-0.3.

Do Preclinical Models Support M701's Mechanism?

In animal studies, M701 demonstrated superior efficacy in inhibiting the growth of human colon cancer cells in xenograft models compared to control antibodies. Additionally, M708, a surrogate molecule of M701 designed for murine studies, significantly prolonged survival in a syngeneic ascites tumor model when administered intraperitoneally, further supporting the mechanism of action and potential clinical benefit.

The molecular design of M701 incorporates several innovative features that enhance its manufacturability and functionality. The antibody consists of a monovalent unit (comprising a heavy chain/light chain pair) and a single-chain unit where the scFv is constructed in a VH-VL orientation connected by a (Gly4Ser)3 linker. The Fc fragments contain specific mutations based on salt bridge and knobs-into-holes technology to prevent mismatched pairing. The glycosylated intact mass of M701 is approximately 128.5 kDa, while the deglycosylated mass is 125.6 kDa.

What Patient Characteristics Inform Treatment Outcomes?

Regarding the patient population, most participants had gastric cancer (approximately 48.8% in the M701 group and 45.0% in the control group), followed by ovarian cancer and colorectal cancer. About 65% of patients in both arms had undergone prior paracentesis. The median number of prior systemic treatment lines was two in both groups, with approximately 30% of patients having received more than three lines of systemic treatment. The systemic therapies used during the study included apatinib mesylate, nivolumab, regorafenib, fruquintinib, paclitaxel albumin-bound, and doxorubicin hydrochloride liposome, with balanced distribution between the two arms.

How Might M701 Reshape Future Management of Malignant Ascites?

These findings position M701 as a promising local therapy for malignant ascites that can be integrated with systemic anticancer treatments. The significant extension of puncture-free survival represents a meaningful clinical benefit that could substantially improve quality of life for patients with this challenging condition. The enhanced benefit observed in patients with higher lymphocyte counts also suggests opportunities for biomarker-guided patient selection.

Could the identification of relative lymphocyte count as a potential predictive biomarker change how we approach patient selection for immunotherapy-based treatments in malignant ascites? The striking difference in outcomes between patients with higher versus lower lymphocyte counts raises important questions about optimizing patient selection and potentially combining M701 with immunomodulatory agents that might enhance lymphocyte function or numbers.

How might the integration of M701 with emerging systemic therapies reshape the treatment landscape for malignant ascites? As new targeted therapies and immunotherapies continue to enter clinical practice, understanding their interaction with local treatments like M701 could lead to more comprehensive management strategies.

While this Phase II trial provides promising evidence for M701's efficacy and safety, several limitations should be acknowledged. The sample size was relatively small, and quality of life data was not comprehensively collected, which would have provided valuable insights into the patient experience. A larger Phase III trial is currently underway to further evaluate M701's efficacy and safety profile, which will help address these limitations and potentially establish M701 as a standard treatment option for malignant ascites.

The development of M701 represents a significant step forward in addressing an unmet need in oncology. By specifically targeting malignant cells within the peritoneal cavity while minimizing systemic exposure, this approach offers a rational strategy to control malignant ascites and potentially improve both quality and quantity of life for patients with advanced epithelial cancers.

Summary

M701, a novel bispecific antibody targeting EpCAM and CD3, has demonstrated significant promise in treating malignant ascites according to results from a Phase II clinical trial conducted across 34 hospitals in China. The study enrolled 84 patients with malignant ascites from gastrointestinal or ovarian cancers who had failed multiple treatment lines. Patients receiving intraperitoneal M701 achieved a median puncture-free survival of 75 days compared to 25 days in the control group receiving paracentesis alone, representing a statistically significant improvement. The benefit was particularly pronounced in patients with higher baseline relative lymphocyte counts, who achieved a median puncture-free survival of 125 days and demonstrated improved overall survival. M701 features an innovative Fab-scFv-Fc structure engineered with moderate CD3 affinity to balance T-cell activation while reducing cytokine release. The treatment showed a manageable safety profile with minimal systemic exposure, as peak serum concentrations remained low while ascites concentrations reached therapeutic levels. Cytokine release syndrome occurred in only 4% of patients and was limited to mild grades. The antibody works by bridging T cells to EpCAM-expressing tumor cells, inducing specific cytotoxicity against cancer cells while sparing normal tissues. Preclinical studies in xenograft and syngeneic models supported the mechanism and efficacy observed clinically. These findings suggest M701 could address a significant unmet need in managing malignant ascites, a condition that severely impacts quality of life in patients with advanced cancers. A larger Phase III trial is currently underway to further establish M701's role in clinical practice and potentially make it a standard treatment option for this challenging condition.